Rhumbline Advisers Kiniksa Pharmaceuticals, Ltd. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$17.63 - $21.74 $8,709 - $10,739	494 Added 0.81%	61,431 $1.21 Million
Q4 2023 Feb 08, 2024	SELL	$14.37 - $19.07 $31,556 - $41,877	-2,196 Reduced 3.48%	60,937 $1.07 Million
Q3 2023 Nov 09, 2023	BUY	$13.62 - $20.2 $52,723 - $78,194	3,871 Added 6.53%	63,133 $1.1 Million
Q2 2023 Aug 08, 2023	BUY	$10.44 - $16.48 $137,505 - $217,058	13,171 Added 28.58%	59,262 $834,000
Q1 2023 May 11, 2023	BUY	$10.7 - $15.79 $17,986 - $26,542	1,681 Added 3.79%	46,091 $496,000
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $16,296 - $24,330	1,427 Added 3.32%	44,410 $665,000
Q3 2022 Nov 10, 2022	BUY	$9.76 - $13.41 $28,684 - $39,411	2,939 Added 7.34%	42,983 $552,000
Q2 2022 Aug 11, 2022	BUY	$7.6 - $11.41 $35,340 - $53,056	4,650 Added 13.14%	40,044 $388,000
Q1 2022 May 12, 2022	BUY	$9.3 - $12.37 $6,854 - $9,116	737 Added 2.13%	35,394 $352,000
Q4 2021 Feb 10, 2022	SELL	$10.39 - $15.15 $8,436 - $12,301	-812 Reduced 2.29%	34,657 $408,000
Q3 2021 Nov 12, 2021	SELL	$11.39 - $16.23 $11,025 - $15,710	-968 Reduced 2.66%	35,469 $404,000
Q2 2021 Aug 05, 2021	BUY	$13.22 - $19.09 $101,463 - $146,515	7,675 Added 26.68%	36,437 $508,000
Q1 2021 May 06, 2021	SELL	$16.68 - $23.97 $27,605 - $39,670	-1,655 Reduced 5.44%	28,762 $532,000
Q4 2020 Feb 10, 2021	BUY	$14.8 - $21.15 $69,722 - $99,637	4,711 Added 18.33%	30,417 $537,000
Q3 2020 Nov 12, 2020	BUY	$15.21 - $25.53 $36,869 - $61,884	2,424 Added 10.41%	25,706 $394,000
Q2 2020 Aug 13, 2020	BUY	$15.08 - $26.0 $96,135 - $165,750	6,375 Added 37.71%	23,282 $593,000
Q1 2020 May 06, 2020	BUY	$11.0 - $19.76 $484 - $869	44 Added 0.26%	16,907 $262,000
Q4 2019 Feb 05, 2020	BUY	$5.24 - $12.96 $1,755 - $4,341	335 Added 2.03%	16,863 $187,000
Q3 2019 Oct 23, 2019	SELL	$8.15 - $15.88 $309 - $603	-38 Reduced 0.23%	16,528 $141,000
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.39 $49,566 - $76,564	3,755 Added 29.31%	16,566 $224,000
Q1 2019 May 01, 2019	BUY	$15.93 - $26.59 $77,451 - $129,280	4,862 Added 61.16%	12,811 $231,000
Q4 2018 Jan 31, 2019	BUY	$16.25 - $28.09 $129,171 - $223,287	7,949 New	7,949 $223,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$33.4 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4.46 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

97.5K
Shares

$2.15 Million
0.11% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$870,271
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$661,200
0.69% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $760M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account